Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease
Status:
Terminated
Trial end date:
2021-08-30
Target enrollment:
Participant gender:
Summary
The primary objective of the placebo-controlled period is to evaluate the safety and
tolerability of BIIB092 in participants with mild cognitive impairment (MCI) due to
Alzheimer's disease (AD) or with mild AD. The secondary objectives of the placebo-controlled
period are to evaluate the efficacy of multiple doses of BIIB092 in slowing cognitive and
functional impairment in participants with MCI due to AD or with mild AD, and to evaluate the
immunogenicity of BIIB092 after multiple doses in participants with MCI due to AD or with
mild AD.
The primary objective of the long-term extension period is to evaluate the long-term safety
and tolerability of BIIB092 in participants with MCI due to AD or with mild AD.